1
|
Stocker M, Blancke Soares A, Liebsch G, Meier RJ, Canis M, Gires O, Haubner F. Quantification of oxygen consumption in head and neck cancer using fluorescent sensor foil technology. Front Oncol 2024; 14:1002798. [PMID: 38390268 PMCID: PMC10882065 DOI: 10.3389/fonc.2024.1002798] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2022] [Accepted: 01/22/2024] [Indexed: 02/24/2024] Open
Abstract
Introduction Head and neck squamous cell carcinoma (HNSCC) patients suffer from frequent local recurrences that negatively impact on prognosis. Hence, distinguishing tumor and normal tissue is of clinical importance as it may improve the detection of residual tumor tissue in surgical resection margins and during imaging-based surgery planning. Differences in O2 consumption (OC) can be used to this aim, as they provide options for improved surgical, image-guided approaches. Methods In the present study, the potential of a fluorescent sensor foil-based technology to quantify OC in HNSCC was evaluated in an in vitro 3D model and in situ in patients. Results In vitro measurements of OC using hypopharyngeal and esophageal cell lines allowed a specific detection of tumor cell spheroids embedded together with cancer-associated fibroblasts in type I collagen extracellular matrix down to a diameter of 440 µm. Pre-surgery in situ measurements were conducted with a handheld recording device and sensor foils with an oxygen permeable membrane and immobilized O2-reactive fluorescent dyes. Lateral tongue carcinoma and carcinoma of the floor of the mouth were chosen for analysis owing to their facilitated accessibility. OC was evaluated over a time span of 60 seconds and was significantly higher in tumor tissue compared to healthy mucosa in the vicinity of the tumor. Discussion Hence, OC quantification using fluorescent sensor foil-based technology is a relevant parameter for the differentiation of tumor tissue of the head and neck region and may support surgery planning.
Collapse
Affiliation(s)
- Magdalena Stocker
- Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital, Ludwig Maximilians University (LMU) Munich, Munich, Germany
| | - Alexandra Blancke Soares
- Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital, Ludwig Maximilians University (LMU) Munich, Munich, Germany
| | - Gregor Liebsch
- PreSens Precision Sensing GmbH, Imaging Solutions, Regensburg, Germany
| | - Robert J Meier
- PreSens Precision Sensing GmbH, Imaging Solutions, Regensburg, Germany
| | - Martin Canis
- Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital, Ludwig Maximilians University (LMU) Munich, Munich, Germany
| | - Olivier Gires
- Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital, Ludwig Maximilians University (LMU) Munich, Munich, Germany
| | - Frank Haubner
- Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital, Ludwig Maximilians University (LMU) Munich, Munich, Germany
| |
Collapse
|
2
|
Harris A, Andl T. Precancerous Lesions of the Head and Neck Region and Their Stromal Aberrations: Piecemeal Data. Cancers (Basel) 2023; 15:cancers15082192. [PMID: 37190121 DOI: 10.3390/cancers15082192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2023] [Revised: 04/04/2023] [Accepted: 04/05/2023] [Indexed: 05/17/2023] Open
Abstract
Head and neck squamous cell carcinomas (HNSCCs) develop through a series of precancerous stages from a pool of potentially malignant disorders (PMDs). Although we understand the genetic changes that lead to HNSCC, our understanding of the role of the stroma in the progression from precancer to cancer is limited. The stroma is the primary battleground between the forces that prevent and promote cancer growth. Targeting the stroma has yielded promising cancer therapies. However, the stroma at the precancerous stage of HNSCCs is poorly defined, and we may miss opportunities for chemopreventive interventions. PMDs already exhibit many features of the HNSCC stroma, such as inflammation, neovascularization, and immune suppression. Still, they do not induce cancer-associated fibroblasts or destroy the basal lamina, the stroma's initial structure. Our review aims to summarize the current understanding of the transition from precancer to cancer stroma and how this knowledge can reveal opportunities and limitations for diagnostic, prognostic, and therapeutic decisions to benefit patients. We will discuss what may be needed to fulfill the promise of the precancerous stroma as a target to prevent progression to cancer.
Collapse
Affiliation(s)
- Ashlee Harris
- Burnett School of Biomedical Sciences, University of Central Florida, 12722 Research Pkwy, Orlando, FL 32826, USA
| | - Thomas Andl
- Burnett School of Biomedical Sciences, University of Central Florida, 12722 Research Pkwy, Orlando, FL 32826, USA
| |
Collapse
|
3
|
Gholami S, Chamorro-Petronacci C, Pérez-Sayáns M, Suárez Peñaranda J, Longatto-Filho A, Baltazar F, Afonso J. Immunoexpression profile of hypoxia-inducible factor (HIF) targets in potentially malignant and malignant oral lesions: a pilot study. J Appl Oral Sci 2023; 31:e20220461. [PMID: 37194791 DOI: 10.1590/1678-7757-2022-0461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2022] [Accepted: 03/30/2023] [Indexed: 05/18/2023] Open
Abstract
Oral potentially malignant disorders (OPMD) are associated with an increased risk of oral squamous cell carcinoma (OSCC). OSCC has an aggressive profile and is the most prevalent among different head and neck malignancies. Most OSCC patients are diagnosed with advanced stage tumors and have a poor prognosis. Cancer cells are able to reprogram their metabolism, even in the presence of oxygen, enhancing the conversion of glucose to lactate via the glycolytic pathway, a phenomenon mainly regulated by hypoxia-inducible factor (HIF) signaling. Thus, several glycometabolism-related biomarkers are upregulated. This study aimed to evaluate the immunoexpression of the HIF targets GLUT1, GLUT3, HK2, PFKL, PKM2, pPDH, LDHA, MCT4, and CAIX in OPMD and OSCC samples, in order to identify potential correlations between biomarkers' immunoexpression, clinicopathological features, and prognostic parameters. OSCC and OPMD samples from 21 and 34 patients (respectively) were retrospectively collected and stained for the different biomarkers by immunohistochemistry. CAIX and MCT4 expressions were significantly higher in OSCC samples when compared with OPMD samples, while the rest were also expressed by OPMD. GLUT3 and PKM2 alone, and the concomitant expression of more than four glycometabolism-related biomarkers were significantly correlated with the presence of dysplasia in OPMD. When considering OSCC cases, a trend toward increased expression of biomarkers and poor clinicopathological features was observed, and the differences regarding HK2, PFKL, LDHA and MCT4 expression were significant. Moreover, HK2 and CAIX were correlated with low survival rates. GLUT1 and GLUT3 were significantly associated with poor outcome when their expression was observed in the hypoxic region of malignant lesions. OPMD and OSCC cells overexpress glycolysis-related proteins, which is associated with aggressive features and poor patient outcome. Further research is needed to deeply understand the glycolic phenotype in the process of oral carcinogenesis.
Collapse
Affiliation(s)
- Shakiba Gholami
- University of Minho, School of Medicine, Life and Health Sciences Research Institute (ICVS), Braga, Portugal
- University of Minho, ICVS/3B's - PT Government Associate Laboratory, Guimarães, Portugal
| | - Cintia Chamorro-Petronacci
- Universidad de Santiago de Compostela, Facultad de Medicina y Odontología, Unidad de Medicina Oral, Cirugía Oral e Implantología, Grupo MedOralRes, Santiago de Compostela, España
- Universidad de Santiago de Compostela, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Grupo ORALRES, Santiago de Compostela, España
| | - Mario Pérez-Sayáns
- Universidad de Santiago de Compostela, Facultad de Medicina y Odontología, Unidad de Medicina Oral, Cirugía Oral e Implantología, Grupo MedOralRes, Santiago de Compostela, España
- Universidad de Santiago de Compostela, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Grupo ORALRES, Santiago de Compostela, España
| | - José Suárez Peñaranda
- Universidad de Santiago de Compostela, Facultad de Medicina y Odontología, Unidad de Medicina Oral, Cirugía Oral e Implantología, Grupo MedOralRes, Santiago de Compostela, España
- Universidad de Santiago de Compostela, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Grupo ORALRES, Santiago de Compostela, España
| | - Adhemar Longatto-Filho
- University of Minho, School of Medicine, Life and Health Sciences Research Institute (ICVS), Braga, Portugal
- University of Minho, ICVS/3B's - PT Government Associate Laboratory, Guimarães, Portugal
- Universidade Estadual Paulista, Faculdade de Medicina, Laboratório de Investigação Médica (LIM 14), São Paulo, Brasil
- Hospital do Câncer de Barretos (Hospital de Amor), Centro de Pesquisa em Oncologia Molecular, São Paulo, Brasil
| | - Fátima Baltazar
- University of Minho, School of Medicine, Life and Health Sciences Research Institute (ICVS), Braga, Portugal
- University of Minho, ICVS/3B's - PT Government Associate Laboratory, Guimarães, Portugal
| | - Julieta Afonso
- University of Minho, School of Medicine, Life and Health Sciences Research Institute (ICVS), Braga, Portugal
- University of Minho, ICVS/3B's - PT Government Associate Laboratory, Guimarães, Portugal
| |
Collapse
|
4
|
Torres López M, Pérez Sayáns M, Chamorro Petronacci C, Barros Angueira F, Gándara Vila P, Lorenzo Pouso A, García García A. Determination and diagnostic value of CA9 mRNA in peripheral blood of patients with oral leukoplakia. J Enzyme Inhib Med Chem 2018; 33:951-955. [PMID: 29745265 PMCID: PMC6009864 DOI: 10.1080/14756366.2018.1466120] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
Abstract
BACKGROUND Oral leukoplakia is one of the most common oral premalignant disorder. The classical evaluation through tissue biopsy is not always valid to evaluate the risk of malignization. MATERIAL AND METHODS RT-qPCR was performed on 47 blood samples (21 patients with leukoplakia, 2 with oral squamous cell carcinoma (OSCC), and 24 healthy patients) and on 11 tissue samples (3 leukoplakia, 4 OSCC, and 4 samples of healthy tissue). RESULTS There are significant differences in expression between the different groups (F = 4.057, p = .006). The Duncan post hoc test shows that the only group that differentiates is the tumour tissue. Using Wilcoxon test, different covariables of patients with leukoplakia were analysed with respect to the group of healthy patients and no significant differences were observed. CONCLUSIONS The diagnostic route through liquid biopsy has not been conclusive in this study, but there are significant differences in the levels analysed in the different tissue samples.
Collapse
Affiliation(s)
- Manuel Torres López
- a Oral Medicine, Oral Surgery and Implantology Unit, Faculty of Medicine and Dentistry , Instituto de Investigación Sanitaria de Santiago (IDIS) , Santiago de Compostela , Spain
| | - Mario Pérez Sayáns
- a Oral Medicine, Oral Surgery and Implantology Unit, Faculty of Medicine and Dentistry , Instituto de Investigación Sanitaria de Santiago (IDIS) , Santiago de Compostela , Spain
| | - Cintia Chamorro Petronacci
- a Oral Medicine, Oral Surgery and Implantology Unit, Faculty of Medicine and Dentistry , Instituto de Investigación Sanitaria de Santiago (IDIS) , Santiago de Compostela , Spain
| | - Francisco Barros Angueira
- b Unidad de Medicina Molecular - Fundación Pública Galega de Medicina Xenómica, Edificio de Consultas planta 2, Hospital Clinico Universitario , Santiago de Compostela , Spain
| | - Pilar Gándara Vila
- a Oral Medicine, Oral Surgery and Implantology Unit, Faculty of Medicine and Dentistry , Instituto de Investigación Sanitaria de Santiago (IDIS) , Santiago de Compostela , Spain
| | - Alejandro Lorenzo Pouso
- a Oral Medicine, Oral Surgery and Implantology Unit, Faculty of Medicine and Dentistry , Instituto de Investigación Sanitaria de Santiago (IDIS) , Santiago de Compostela , Spain
| | - Abel García García
- a Oral Medicine, Oral Surgery and Implantology Unit, Faculty of Medicine and Dentistry , Instituto de Investigación Sanitaria de Santiago (IDIS) , Santiago de Compostela , Spain
| |
Collapse
|
5
|
Kujan O, Shearston K, Farah CS. The role of hypoxia in oral cancer and potentially malignant disorders: a review. J Oral Pathol Med 2016; 46:246-252. [PMID: 27560394 DOI: 10.1111/jop.12488] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/30/2016] [Indexed: 12/22/2022]
Abstract
Oral and oropharyngeal cancer are major health problems globally with over 500 000 new cases diagnosed annually. Despite the fact that oral cancer is a preventable disease and has the potential for early detection, the overall survival rate remains at around 50%. Most oral cancer cases are preceded by a group of clinical lesions designated 'potentially malignant disorders'. It is difficult to predict if and when these lesions may transform to malignancy, and in turn it is difficult to agree on appropriate management strategies. Understanding underlying molecular pathways would help in predicting the malignant transformation of oral potentially malignant disorders and ultimately identifying effective methods for early detection and prevention of oral cancer. Reprogramming energy metabolism is an emerging hallmark of cancer that is predominantly controlled by hypoxia-induced genes regulating angiogenesis, tumour vascularization, invasion, drug resistance and metastasis. This review aims to highlight the role of hypoxia in oral carcinogenesis and to suggest future research implications in this arena.
Collapse
Affiliation(s)
- Omar Kujan
- School of Dentistry, Oral Health Centre, The University of Western Australia, Nedlands, WA, Australia.,Department of Oral and Maxillofacial Sciences, Al-Farabi Colleges, Riyadh, Saudi Arabia
| | - Kate Shearston
- School of Dentistry, Oral Health Centre, The University of Western Australia, Nedlands, WA, Australia
| | - Camile S Farah
- School of Dentistry, Oral Health Centre, The University of Western Australia, Nedlands, WA, Australia.,Australian Centre for Oral Oncology Research & Education, School of Dentistry, The University of Western Australia, Nedlands, WA, Australia
| |
Collapse
|
6
|
Spugnini EP, Sonveaux P, Stock C, Perez-Sayans M, De Milito A, Avnet S, Garcìa AG, Harguindey S, Fais S. Proton channels and exchangers in cancer. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES 2014; 1848:2715-26. [PMID: 25449995 DOI: 10.1016/j.bbamem.2014.10.015] [Citation(s) in RCA: 142] [Impact Index Per Article: 14.2] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 07/30/2014] [Revised: 10/07/2014] [Accepted: 10/13/2014] [Indexed: 12/18/2022]
Abstract
Although cancer is characterized by an intratumoral genetic heterogeneity, a totally deranged pH control is a common feature of most cancer histotypes. Major determinants of aberrant pH gradient in cancer are proton exchangers and transporters, including V-ATPase, Na+/H+ exchanger (NHE), monocarboxylate transporters (MCTs) and carbonic anhydrases (CAs). Thanks to the activity of these proton transporters and exchangers, cancer becomes isolated and/or protected not only from the body reaction against the growing tumor, but also from the vast majority of drugs that when protonated into the acidic tumor microenvironment do not enter into cancer cells. Proton transporters and exchangers represent a key feature tumor cells use to survive in the very hostile microenvironmental conditions that they create and maintain. Detoxifying mechanisms may thus represent both a key survival option and a selection outcome for cells that behave as unicellular microorganisms rather than belonging to an organ, compartment or body. It is, in fact, typical of malignant tumors that, after a clinically measurable yet transient initial response to a therapy, resistant tumor clones emerge and proliferate, thus bursting a more malignant behavior and rapid tumor progression. This review critically presents the background of a novel and efficient approach that aims to fight cancer through blocking or inhibiting well characterized proton exchangers and transporters active in human cancer cells. This article is part of a Special Issue entitled: Membrane channels and transporters in cancers.
Collapse
Affiliation(s)
- Enrico Pierluigi Spugnini
- Anti-Cancer Drug Section, Department of Drug Research and Medicine Evaluation, Istituto Superiore di Sanità (National Institute of Health), Rome, Italy
| | - Pierre Sonveaux
- Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology, Université Catholique de Louvain (UCL), Brussels, Belgium
| | - Christian Stock
- Department of Gastroenterology, Hannover Medical School, Hannover, Germany
| | - Mario Perez-Sayans
- Oral Medicine, Oral Surgery and Implantology Unit, Faculty of Medicine and Dentistry, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain
| | - Angelo De Milito
- Cancer Center Karolinska, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
| | - Sofia Avnet
- Laboratory for Orthopaedic Pathophysiology and Regenerative Medicine, Istituto Ortopedico Rizzoli, Bologna, Italy
| | - Abel Garcìa Garcìa
- Oral Medicine, Oral Surgery and Implantology Unit, Faculty of Medicine and Dentistry, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain
| | | | - Stefano Fais
- Anti-Cancer Drug Section, Department of Drug Research and Medicine Evaluation, Istituto Superiore di Sanità (National Institute of Health), Rome, Italy.
| |
Collapse
|
7
|
Pérez-Sayáns M, Suárez-Peñaranda JM, Torres-López M, Supuran CT, Gándara-Vila P, Gayoso-Diz P, Barros-Angueira F, Gallas-Torreira M, García-García A. The use of CA-IX as a diagnostic method for oral leukoplakia. Biotech Histochem 2014; 90:124-31. [PMID: 25297562 DOI: 10.3109/10520295.2014.965276] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
The presence and degree of dysplasia are important diagnostic and prognostic criteria for oral leukoplakia, but evaluation of dysplasia is difficult and subjective. Carbonic anhydrase-IX (CA-IX) is expressed primarily in tumor cells and is considered a specific hypoxia marker. We investigated the role of CA-IX in oral leukoplakia. We investigated 30 specimens of oral leukoplakia and 35 dysplasia specimens adjacent to the tumor margin. We analyzed clinical variables including age, sex, degree of dysplasia, and smoking, clinical appearance of leukoplakia, number of lesions, location, size, clinical monitoring, malignant transformation and recurrence. For the immunohistochemical study, we used a noncommercial monoclonal antibody against human CA-IX MAb M75. We found greater CA-IX positivity in nonsmokers, erythroplakia and mottled leukoplakia, those located on the tongue, patients with multiple lesions, 2-4 cm leukoplakias and in recurrent cases, although differences were not statistically significant. All lesions in all samples without dysplasia were negative for CA-IX; however, for all other categories of dysplasia, the percentages of positivity and negativity varied. Regarding the diagnostic index values, we found a sensitivity of 32%, specificity of 100%, a positive predictive value of 100% and a negative predictive value of 13%. Leukoplakias appear mainly in females and potentially are malignant; more than 90% have some degree of dysplasia, and therefore require close clinical and histopathological monitoring. The CA-IX immunohistochemical marker may be useful for screening samples without dysplasia owing to its high specificity.
Collapse
Affiliation(s)
- M Pérez-Sayáns
- Oral Medicine, Oral Surgery and Implantology Unit, Faculty of Medicine and Dentistry, Institute of Sanitary Research of Santiago , Entrerrios s/n, Santiago de Compostela C.P. 15782 , Spain
| | | | | | | | | | | | | | | | | |
Collapse
|